Clinical Study

A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study To Evaluate Efficacy And Safety Of Dcvac/Pca Versus Placebo In Men With Metastatic Castration Resistant Prostate Cancer Eligible For 1St Line Chemotherapy

Posted Date: Jul 8, 2017

  • Investigator: Nagla Abdel Karim
  • Co-Investigator: Nagla Abdel Karim
  • Specialties: Hematology/Oncology, Prostate Cancer, Oncology, Cancer
  • Type of Study: Drug

The main purpose of this study is to find out if the study drug given with standard of care chemotherapy makes people with prostate cancer live longer than giving the standard of care chemotherapy and a placebo. The investigators also hope to learn about

Criteria:

To Be Eligible For This Study, Patients Must Have Advanced Cancer Of The Prostate For Which The Doctor Has Recommended Treatment With Standard Of Care Chemotherapy (Docetaxel And Prednisone).

Keywords:

Sp005, Prostate, Castrate-Resistant , Cancer, Metastatic

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    NIDA Director Nora Volkow to Speak on Opioid Crisis Nov. 27

    Nora Volkow, MD, director of the National Institute on Drug Abuse (NIDA), willbe the keynote speaker at a public symposium on tackling the opioid crisis onMonday, Nov. 27